Voclosporin licensed in China for transplantation
This article was originally published in Scrip
Executive Summary
Isotechnika Pharma saw its share price jump up by 30% earlier this week following news that it had signed a development and commercialisation deal with China's 3SBio for voclosporin, an investigational next generation calcineurin inhibitor for the prevention of organ rejection following transplantation and the treatment of autoimmune diseases.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.